Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“Hot off the Press – published in Cell Press journal Trends in Cancer. Thrilled to share our new piece.
‘Next-generation tumor-agnostic targets on the horizon’ led by the visionary rising star trio Drs. Niamh Coleman (Ireland), Jia Jenny Liu (Australia) and Juliana Rodrigues Beal (Brazil).
Today: MSI‑H/dMMR, TMB‑H, NTRK/RET, BRAF V600E, HER2 3+.
Tomorrow: KRAS variants, MTAP loss, TP53 Y220C, FGFR2, NRG fusions and much more.
We also show a hypothetical KRAS tumor-agnostic trial design, investigators, PI and Industry colleagues from Pharma- feel free to reach out and I can share the trial design. I really want to get KRAS inhibitors approved for all RAS + cancers.
Such a delight and honor to work with and mentor this truly global powerhouse team.”
Title: Next-generation tumor-agnostic targets on the horizon.
Authors: Niamh Coleman, Jia Liu, Juliana Beal, Vivek Subbiah.
You can also read ‘The Big Questions in Cancer Immunotherapy: Can We Build an Immune System Inside the Tumor?‘.
